← Back to headlines
Novo Nordisk Stock Sinks 9% After Heart Drug Fails Clinical Trial
Novo Nordisk's stock dropped by 9% following the announcement that its experimental heart drug did not meet expectations in a recent clinical trial.
31 Jul, 20:50 — 31 Jul, 20:50
Sources
Showing 1 of 1 sources
